Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.79 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 8/20 | 0.45 |
| ▸ | PDE2A | O00408 | 2/20 | 0.43 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.42 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22407181 | 1.00 | AHR (0.79) | AHRADORA3ABL1PDE2ASCN10A | |
| SCHEMBL22407132 | 0.92 | AHR (0.74) | AHRADORA3ABL1PDE2ASCN10A | |
| SCHEMBL22407232 | 0.92 | AHR (0.74) | AHRADORA3ABL1PDE2ASCN10A | |
| SCHEMBL25581078 | 0.91 | AHR (0.76) | AHRADORA3PDE2ASCN10ASCN9A | |
| SCHEMBL25581080 | 0.91 | AHR (0.76) | AHRADORA3PDE2ASCN10ASCN9A | |
| SCHEMBL21001400 | 0.90 | AHR (0.80) | AHRADORA3PDE2ASCN10ASCN9A | |
| SCHEMBL21001401 | 0.90 | AHR (0.80) | AHRADORA3PDE2ASCN10ASCN9A | |
| SCHEMBL22407196 | 0.89 | AHR (0.73) | AHRADORA3ABL1PDE2ASCN10A | |
| SCHEMBL22407194 | 0.89 | AHR (0.73) | AHRADORA3ABL1PDE2ASCN10A | |
| SCHEMBL22407223 | 0.88 | AHR (0.72) | AHRADORA3ABL1PDE2ASCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3713926-B1 | 2-HETARYLPYRIMIDINE-4-CARBOXAMIDES AS ARYL HYDROCARBON RECEPTOR ANATGONISTS | BAYER AG (DE) | 2023-06-07 | — | — | EP | claimed |
| US-11304946-B2 | 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2022-04-19 | — | — | US | claimed |
| US-20200289509-A1 | 2-HETARYLPYRIMIDINE-4-CARBOXAMIDES AS ARYL HYDROCARBON RECEPTOR ANATGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-09-17 | — | — | US | claimed |
| EP-3713926-B1 | 2-HETARYLPYRIMIDINE-4-CARBOXAMIDES AS ARYL HYDROCARBON RECEPTOR ANATGONISTS | BAYER AG (DE) | 2023-06-07 | — | — | EP | disclosed |
| EP-3713926-B1 | 2-HETARYLPYRIMIDINE-4-CARBOXAMIDES AS ARYL HYDROCARBON RECEPTOR ANATGONISTS | BAYER AG (DE) | 2023-06-07 | — | — | EP | disclosed |
| US-11304946-B2 | 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2022-04-19 | — | — | US | disclosed |
| US-11304946-B2 | 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2022-04-19 | — | — | US | disclosed |
| US-20200289509-A1 | 2-HETARYLPYRIMIDINE-4-CARBOXAMIDES AS ARYL HYDROCARBON RECEPTOR ANATGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-09-17 | — | — | US | disclosed |
| US-20200289509-A1 | 2-HETARYLPYRIMIDINE-4-CARBOXAMIDES AS ARYL HYDROCARBON RECEPTOR ANATGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289509-A1 | 2-HETARYLPYRIMIDINE-4-CARBOXAMIDES AS ARYL HYDROCARBON RECEPTOR ANATGONISTS | AHR, ARNT, HRH2 | AHR 1/4885ADORA3 302/4885ABL1 496/4885 |
| US-11304946-B2 | 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor antagonists | AHR, ARNT, HRH2 | AHR 1/4885ADORA3 272/4885ABL1 665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.